In this study, we provided evidence for PBK as a pan-cancer biomarker based on gene expression and survival data and analyses of immune cell infiltration, TFs, miRNAs, pharmacogenomics, and related intracellular signaling pathways. This evidence concerns the gene PBK and cancer.